Starting Phase IIa Clinical Trials

What happens during an acute asthma attack?

Acute asthma attacks trigger the TRPV1 receptor* in the carotid bodies that control breathing.

1. An acute asthma attack leads to an increase in systemic levels of LPA (lysophosphatidic acid) and other inflammatory mediators.

2. LPA and other inflammatory mediators activate the TRPV1 receptor* in the carotid bodies (clusters of neurons in the neck that control breathing).

3. Neurons from the carotid bodies send the information to the brain cardiorespiratory center. 

4. Vagus nerve simulations trigger bronchoconstriction (narrowing of the airways). 

*TRPV1 (Transient Receptor Potential Vanilloid 1) is an ion channel present on sensory neurons which is activated by heat, protons, capsaicin and a variety of endogenous lipids and inflammatory mediators.

How does AazeinTx aim to prevent an acute asthma attack?

NEO6860 is a TRPV1 antagonist being developed to prevent acute asthma attacks. NEO6860 has a robust safety profile and is clinic-ready.
  • Oral (non-airway) delivery
  • A Phase II-ready drug
  • Best-in-class drug with a specific action against TRPV1
  • Rapid-acting
  • Relieves bronchoconstriction by primarily acting on neurons and their reflex regulation of airways
  • Potential to be used chronically as a long-term prevention against asthma

Oral Delivery

Rapid Effect

Specific TRPV1 Action

AazeinTx is currently raising capital